Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four-week study

被引：44

作者：

Cantini, Fabrizio

Niccoli, Laura

Benucci, Maurizio

Chindamo, Daniela

Nannini, Carlotta

Olivieri, Ignazio

Padula, Angela

Salvarani, Carlo

机构：

[1] Osped Prato, Div Med 2, Unita Reumatol, I-59100 Prato, Italy

[2] New S Giovanni Dio Hosp, Florence, Italy

[3] San Carlo Hosp, Potenza, Italy

[4] Arcispedale S Maria Nuova, Reggio Emilia, Italy

来源：

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2006年 / 55卷 / 05期

关键词：

PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; STURE REGISTRY; DOUBLE-BLIND; TNF-ALPHA; EFFICACY; SPONDYLOARTHROPATHIES; MULTICENTER; THERAPY;

D O I：

10.1002/art.22236

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：812 / 816

页数：5

共 29 条

[1]

Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO

[2]

2-F

[3]

Ang HTS, 2003, J RHEUMATOL, V30, P2315

[4] Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].

Brandt, J ;

Khariouzov, A ;

Listing, J ;

Haibel, H ;

Sörensen, H ;

Grassnickel, L ;

Rudwaleit, M ;

Sieper, J ;

Braun, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675

[5] Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis -: An open, observational, extension study of a three-month, randomized, placebo-controlled trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Burmester, G ;

Golder, W ;

Gromnica-Ihle, E ;

Kellner, H ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Reddig, J ;

Sieper, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2224-2233

[6] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[7] International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis [J].

Braun, J ;

Pham, T ;

Sieper, J ;

Davis, J ;

van der Linden, S ;

Dougados, M ;

van der Heijde, D .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :817-824

[8] USE OF IMMUNOHISTOLOGIC AND IN-SITU HYBRIDIZATION TECHNIQUES IN THE EXAMINATION OF SACROILIAC JOINT BIOPSY SPECIMENS FROM PATIENTS WITH ANKYLOSING-SPONDYLITIS [J].

BRAUN, J ;

BOLLOW, M ;

NEURE, L ;

SEIPELT, E ;

SEYREKBASAN, F ;

HERBST, H ;

EGGENS, U ;

DISTLER, A ;

SIEPER, J .

ARTHRITIS AND RHEUMATISM, 1995, 38 (04) :499-505

[9] Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis [J].

Calin, A ;

Dijkmans, BAC ;

Emery, P ;

Hakala, M ;

Kalden, J ;

Leirisalo-Repo, M ;

Mola, EM ;

Salvarani, C ;

Sanmartí, R ;

Sany, J ;

Sibilia, J ;

Sieper, J ;

van der Linden, S ;

Veys, E ;

Appel, AM ;

Fatenejad, S .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) :1594-1600

[10]

Cantini F, 2005, ARTHRITIS RHEUM-US, V52, pS560

← 1 2 3 →